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ABSTRACT 
Background: The Losartan Intervention For End- 
point reduction i  hypertension (LIFE) study found that 
a losartan-based regimen, compared with an atenolol- 
based regimen, resulted in a significantly ower risk of 
stroke in hypertensive patients with left ventricular hy- 
pertrophy, despite similar eductions in blood pressure. 
Objective: The purpose of this review was to exam- 
ine the molecular and pharmacologic mechanisms that 
may be associated with the different outcomes observed 
in the LIFE study. 
Methods: A PubMed/MEDLINE search of English- 
language articles (1990 to February 2006) with the 
terms angiotensin H antagonists or AIIAs or angio- 
tensin receptor blockers or losartan or atenolol or 
beta blocker and terms including, but not limited to, 
atherosclerosis, left ventricular hypertrophy, carotid 
artery hypertrophy, fatty streaks, atrial fibrillation, 
arrhythmias, endothelial function, myocyte hypertro- 
phy, myocardial fibrosis, platelet aggregation, tissue 
factor, plasminogen activator inhibitor-I, PAI-1, anti- 
inflammatory, uric acid, or oxidative stress. 
Results: Losartan's ignificant effect on stroke may 
be related to several possible mechanisms that are in- 
dependent of blood-pressure r ductions. These include 
improvements in endothelial function and vascular 
structure; decreases in vascular oxidative stress; re- 
ductions in left ventricular hypertrophy, reductions 
in myocardial fibrosis, or both; and modulation of 
atherosclerotic disease progression. Although some of 
these effects may be shared by other angiotensin II re- 
ceptor antagonists (AliAs), and perhaps other anti- 
hypertensive classes (eg, angiotensin-converting e - 
zyme inhibitors), the ability of losartan to lower 
serum uric acid levels--a proposed independent risk 
factor for cardiovascular disease--appears to be a 
molecule-specific effect. Alternative xplanations of 
the results of the LIFE study have also been hypothe- 
sized, including inappropriate choice of atenolol as an 
active comparator and differences in central pulse 
pressures between study groups. 
Conclusions: This review of the literature suggests 
that losartan (and perhaps other AliAs) may possess a
number of properties, independent of its antihyper- 
tensive ffects, that may be associated with decreased 
vulnerability of the plaque, myocardium, and blood. 
(Clin Ther. 2006;28:832-848) Copyright © 2006 Excerpta 
Medica, Inc. 
Key words: stroke, angiotensin II antagonists, lo- 
sartan, atenolol, J3-blockers, angiotensin II receptor, 
atherosclerotic plaque, hyperuricemia, rrhythmias, 
thrombosis, inflammation. 
INTRODUCTION 
Despite evidence of the importance of reducing blood 
pressure (BP), hypertension continues to be one of the 
most commonly occurring diseases in humans) Stroke 
is the most frequent complication i hypertensive pa- 
tients. 2 Indeed, hypertension has been considered an 
underlying factor in -70% of strokes) In 8 recently 
completed hypertension trials including 55,110 pa- 
tients, 2057 strokes and 1603 myocardial infarctions 
(MIs) were reported) The relationship of stroke mor- 
tality to BP is strong and direct, regardless of age. 4 
In the Losartan Intervention For Endpoint reduction 
in hypertension (LIFE) study in hypertensive patients 
with left ventricular hypertrophy (LVH), the group of 
patients who received losartan had a 13.0% relative 
risk reduction in the occurrence of the primary com- 
posite end point of cardiovascular (CV) mortality, 
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stroke (fatal and nonfatal), and MI (P = 0.021) and 
a 24.9% relative risk reduction in fatal or nonfatal 
stroke (P = 0.001) compared with patients receiving an 
atenolol-based regimen. 5 The LIFE study compared 
losartan-based therapy with atenolol-based therapy 
according to a double-blind, randomized, parallel- 
group design in 9193 patients aged 55 to 80 years with 
hypertension (sitting BP, 160-200/95-115 mm Hg) 
and LVH ascertained by electrocardiography. 5 Pa- 
tients were initially randomized to losartan 50 mg 
plus placebo or atenolol 50 mg plus placebo. After 
2 months, hydrochlorothiazide (HCTZ) 12.5 mg was 
added to the treatment regimen if the BP was not at or 
below goal BP (ie, <140/90 mm Hg). If, at month 4, 
the pressure was not adequately controlled, the dose of 
double-blind therapy was doubled to losartan 100 mg 
or atenolol 100 mg plus 12.5 mg HCTZ. In patients 
whose BP was still not controlled at month 6, ad- 
ditional open-label antihypertensive medication, in- 
cluding upward titration of HCTZ, was added to 
the treatment regimen. The dosage of HCTZ could be 
increased; additionally, or alternatively, any other an- 
tihypertensive drug (except angiotensin-converting 
enzyme inhibitors, angiotensin II type 1 receptor an- 
tagonists [AliAs], or J3-blockers) could be added at the 
discretion of the investigator. Outcomes favoring losar- 
tan were observed espite similar reductions in BP, 
suggesting that losartan's antistroke ffects may have 
been independent of BP reduction. At the end of follow- 
up or last visit before a primary end point event, the 
mean sitting trough BP fell by 30.2/16.6 mm Hg in the 
losartan group and by 29.1/16.8 mm Hg in the atenolol 
group (P = 0.015 for systolic and P = NS for diastolic). 
Overall, the time-averaged difference in mean arterial 
pressure was 0.1 mm Hg in favor of atenolol, which 
was not statistically significant. 
Atherothrombotic stroke was the most common 
form of stroke observed in the LIFE study, and the ef- 
fects of losartan were greatest for this type of stroke. 6
According to secondary analyses of LIFE data, pa- 
tients who received a losartan-based treatment had 
significant reductions in the risk of atherothrombotic 
stroke (hazard ratio [HR], 0.72 [95% CI, 0.59-0.88; 
P = 0.001]) and fatal stroke (HR, 0.65 [95% CI, 
0.43-0.96]; P = 0.032) compared with atenolol-based 
therapy. 6 Similar risk reductions were observed for 
hemorrhagic and embolic stroke, but these stroke 
subtypes were not significantly different between the 
losartan and atenolol groups. 6This observation raises 
several questions. First, does losartan exert antithrom- 
botic actions beyond lowering BP? Second, are these 
actions dependent on the angiotensin AT 1 receptor? 
And third, are these actions common to all AIIAs? 
Naghavi et al 7,s proposed 3 factors as possible 
contributors to atherothrombotic events: plaques vul- 
nerable to rupture, myocardium vulnerable to fatal 
arrhythmias, and blood prone to inflammation and 
thrombosis. Potentially, these factors may be targets 
of losartan's action. The purpose of this review was 
to examine the molecular and pharmacologic mecha- 
nisms that may be associated with the different out- 
comes observed in the LIFE study. 
M ETH O DS 
A PubMed/MEDLINE search of English-language ar-
ticles (1990 to February 2006) was used to identify 
possible pharmacologic mechanisms ofaction. Searches 
were conducted by combining the terms angiotensin H 
antagonists or AIIAs or angiotensin receptor blockers 
or losartan or atenolol or beta blocker with terms in- 
cluding, but not limited to, atherosclerosis, left ven- 
tricular hypertrophy, carotid artery hypertrophy, fatty 
streaks, atrial fibrillation, arrhythmias, endothelial 
function, myocyte hypertrophy, myocardial fibrosis, 
platelet aggregation, tissue factor, plasminogen activa- 
tor inhibitor-I, PAI-1, anti-inflammatory, uric acid, or 
oxidative stress. Articles describing pathophysiologic 
effects of angiotensin II (AII) and molecular mechanisms 
of pharmacologic action of losartan pertinent to the 
LIFE study were, in the opinion of this author, appro- 
priate for review. 
LOSARTAN AND VULNERABLE PLAQUE 
Atherosclerosis can be viewed as a specialized type of 
chronic inflammation. 9 Atherogenic factors promote 
the attachment and proliferation of mononuclear cells 
on the luminal surface of the arterial wall; these cells 
eventually migrate across the endothelium and accu- 
mulate in the intima. 1° In the presence of oxidized 
low-density lipoprotein cholesterol (LDL-C), mono- 
cytes are converted to activated macrophages and take 
up lipoprotein particles, resulting in their conversion 
to foam cells. 11 The continued formation of foam cells 
and their accumulation i the intima, along with the 
migration of smooth muscle cells, lead to the develop- 
ment of a fatty streak. 9The fatty streak progresses to 
fibrofatty and fibrous plaques, which are character- 
ized by recruitment ofextracellular matrix components 
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and increased eposition of intracellular and extracel- 
lular lipid. 9 In the experience of this author, unstable 
plaques (which are prone to rupture) are characterized 
by a thin fibrous cap, a high foam-cell content, and 
expression of various metalloproteinases. 
Endothelial Dysfunction 
Endothelial dysfunction is an early feature of athero- 
sclerosis and contributes to the atherosclerotic process 
by promoting abnormal vasomotion, infiltration of 
inflammatory cells, and increased coagulation. 12 AII 
promotes endothelial dysfunction through several 
mechanisms, one of which is inactivation of nitric 
oxide. 13 In a study of 25 patients with atherosclerotic 
disease, a 20-minute infusion of losartan 250 tlg/min 
improved coronary vasomotion during flow-mediated 
dilation in response to adenosine from a mean (SD) of 
5.6% (1.5%) to 8.9% (1.8%) (P = 0.02). 14 Similarly, 
in 31 patients with atherosclerosis, treatment with oral 
losartan 25 to 50 mg for 8 weeks improved brachial 
artery vasodilation (mean [SD], 1.4% [0.9%] to 3.2% 
[0.8%]; P = 0.03) and significantly increased serum 
nitrogen oxide levels (mean [SD], 21.6 [1.7] to 26.7 
[2.4] tlmol/L; P = 0.008). is Six weeks of treatment with 
candesartan 16mg/d has also been associated with an 
improved forearm blood flow response during reac- 
tive hyperemia n a randomized, ouble-blind study of 
47 hypercholesterolemic patients with LDL-C > 160 mg/dL 
(approximate change, 31% vs 5% with placebo; P < 
0.05). 16 A similar improvement in flow-mediated dila- 
tor response to hyperemia with candesartan 16 mg/d 
for 2 months was noted in a randomized, ouble-blind, 
placebo-controlled crossover study in 45 patients with 
mild to moderate hypertension. 17 Compared with 
placebo, candesartan was associated with a significant 
increase in flow-mediated ilator response from a 
mean (SD) of 5.17% (0.24%) at baseline to 6.22% 
(0.26%) at the end of 2 months (P < 0.001). 17 
It seems possible that another mechanism by which 
AII may promote ndothelial dysfunction is through 
augmented expression of endothelial adhesion mole- 
cules and, in turn, stimulation of leukocyte adhesion 
to endothelial cells. For instance, it has been reported 
that AII upregulates intercellular adhesion molecule 
(ICAM-1) expression by cultured human vascular en- 
dothelial cells in vitro derived from umbilical cord 
veins and stimulates in vitro and in vivo soluble 
ICAM-1 release. 18 In a separate series of experiments 
involving patients with essential hypertension, treat- 
ment for 4 weeks with losartan 50 mg/d (Figure 1, 
n = 5), but not treatment with atenolol 50 mg QD (n = 
4 [data not shown in figure]), was found to blunt the 
ICAM-1 response to AII. is 
An early event in atherosclerosis is hypertrophy of
the arterial wall, 19 and a reliable surrogate measure- 
ment is carotid intima-media thickness. 2°,21 In rabbits 
fed high-cholesterol diets, administration of losartan 
(25 mg/d for 10 weeks) was associated with signifi- 
cant reductions in intimal proliferation and the ratio 
of intima to media in the aorta (both, P < 0.01 vs 
high-cholesterol diet alone). 22 In hypertensive patients 
who were treated for 1 year with losartan, significant 
reductions in mean (SD) media width to lumen diam- 
eter of gluteal arteries (from 8.4% [0.4%] at baseline 
to 6.7% [0.3%] at 1 year; P < 0.01) were observed, 
whereas treatment with atenolol was not associated 
with a significant change (from 8.3% [0.3%] at base- 
line to 8.8% [0.5%] at the end of treatment). 23 The 
study involved obtaining luteal subcutaneous biop- 
sies under local anesthesia from 19 patients randomly 
assigned to treatment with 50 mg of losartan or ateno- 
lol in a double-blind fashion. Similar improvements in 
vascular structure in hypertensive patients have also 
been reported with irbesartan. 24
Vascular Oxidative Stress 
Atherosclerosis is initiated and amplified by vascu- 
lar oxidative stress. 25 AII has been implicated in this 
process through a variety of mechanisms involving 
alteration of lipid synthesis, lipid oxidation, and lipid 
entry into susceptible endothelium. 
AII (10 -7 M for 18 hours at 37°C) has been shown 
to increase in vitro cellular cholesterol biosynthesis 
(measured by 3H acetate incorporation i to choles- 
terol) by 44%, 34%, and 30%, respectively, inhuman 
monocyte-derived macrophages, in mouse peritoneal 
macrophages, and in J-774A.1 macrophage-like c ll 
line. 26 This effect can be completely attenuated by 
losartan at a concentration f 10 -5 M. 26 In addition, 
AII enhances LDL-C oxidation by stimulating the ac- 
tivity of nicotinamide adenine dinucleotide phosphate 
oxidases in vascular smooth muscle cells (VSMCs) 
and endothelial cells. 27-29 In animal models of athero- 
sclerosis, losartan was associated with a significant 
attenuation of aortic atherosclerotic lesions (P = 
0.001), 3° a significant reduction in LDL-C oxidation 
in apolipoprotein(E)-deficient mice after 10 weeks of 
treatment (P < 0.005 vs placebo), 31 and a significant 
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Figure 1. Effect ofangiotensin II infusion (at an initial rate of 1 ng/kg per minute, increased every 30 minutes by 
2 ng/kg per minute) on circulating intercellular adhesion molecule (ICAM-1) levels in patients with es- 
sential hypertension ( = 5) before and after 4 weeks on placebo or Iosartan 50 mg/d. *P < 0.05 versus 
baseline; tp < 0.003 versus time; *P < 0.002 versus time 0; §P < 0.003 versus baseline; lip < 0.0001 ver- 
sus time 0; ~P < 0.0001 versus baseline. Reproduced with permissionJ 8 
reduction in the susceptibility of LDL-C to in vitro 
oxidation (P < 0.05) in hypercholesterolemic onkeys 
at the end of 6 weeks of treatment. 32In a randomized, 
prospective, crossover study, hypertensive patients 
(n = 40) with type 2 diabetes who received losartan 
50 mg/d for 16 weeks experienced significant reduc- 
tions in LDL-C oxidation (determined by malondi- 
aldehyde [MDA] with the thiobarbituric acid-reactive 
substances assay with and without cupric sulfate) after 
16 weeks (P = 0.001). 33 Values for LDL-oxidation 
with cupric sulfate decreased from 40.3 nmol MDA/mg 
protein at baseline to 34.6 nmol MDA/mg protein after 
losartan (P = 0.001). 
Lectin-like oxidized low-density l ipoprotein 
(Ox-LDL) receptor (LOX-1) expression is upregulat- 
ed by All in cultured human coronary artery endothe- 
lial cells and in primary cultures of human umbilical 
vein endothelial cells. 34,35 In hypercholesterolemic 
rabbits, losartan 25 mg/kg daily for 10 weeks was as- 
sociated with attenuated aortic intimal proliferation 
(P < 0.01) and markedly decreased LOX-1 messenger 
RNA (mRNA, P < 0.01), and LOX-1 expression de- 
termined immunohistochemically (no statistical com- 
parison given). 36 In addition, losartan 50 mg/d for 
4 weeks was associated with Ox-LDL uptake, as indi- 
cated by a 78% decrease in Ox-LDL cell association 
and a 21% reduction in Ox-LDL degradation, as well 
as a reduction in the expression of the Ox-LDL recep- 
tor CD36 by 540/0. 37 
Collectively, the above studies indicate a key role for 
All in the initiation and magnification of the athero- 
sclerotic process. Although likely, it is not clear whether 
Ali's effects on this process are mediated by the AT 1 
receptor or whether other AliAs have mechanisms of 
action similar to those of losartan. 
LOSARTAN AND VULNERABLE MYOCARDIUM 
It is common knowledge that cardiac arrhythmias 
occur frequently in hypertensive patients, and that the 
presence and complexity of arrhythmias may influ- 
ence the morbidity and mortality of patients, especial- 
ly those in relation to the occurrence of stroke. Along 
with diastolic dysfunction of the left ventricle and 
changes in left atrial size and function, LVH emerges 
as the main risk factor for arrhythmias in patients with 
hypertension. 38 In fact, it has been shown that LVH is 
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associated with proarrhythmic repolarization changes 
and increased occurrence of atrial fibrillation and ven- 
tricular arrhythmias) TM 
Myocardial Fibrosis 
LVH is characterized by increased extracellular ma- 
trix deposition (ie, myocardial fibrosis) and increased 
myocyte size (ie, myocyte hypertrophy). Myocardial 
fibrosis results from increased accumulation of fibril- 
lar collagen types I and III throughout the septum and 
free wall of the left ventricle 42-44 and is thought to 
promote abnormalities of cardiac function, coronary 
reserve, and electrical activity. 4s In particular, it has 
been reported that hypertensive patients with LVH 
and arrhythmias exhibited higher myocardial collagen 
tissue deposition and left ventricular mass than pa- 
tients without arrhythmias. 4s
Various lines of evidence suggest hat systemically 
produced All, locally produced All, or both may par- 
ticipate in the development of myocyte hypertrophy 
and myocardial fibrosis that accompany hypertension 
via activation of the AT 1 receptor in cardiac myocytes 46
and fibroblasts. 47 Therefore, losartan might exert an 
antiarrhythmic effect by inducing regression of LVH 
and reduction of myocardial fibrosis. This is support- 
ed by the fact that significant reductions in LVH, myo- 
cardial fibrosis, or both have been reported to occur 
with losartan i hypertensive patients, 4s-s~ hypertensive 
animals, s4-s~ rat models of hypertension, sr-s9 and ani- 
mal models of MI (all, P < 0.05). ~°-~4 
Further studies have found that these effects were 
evident at doses ineffective for reducing BP ~s and in 
animals in which BP was not normalizedT, ~7 This ef- 
fect of losartan was reproduced in hypertensive patients 
in whom reduction of collagen synthesis and myocar- 
dial fibrosis was associated with decreased myocardial 
stiffness (Figure 2). sl,~s Additional support came from 
the LIFE study, in which all patients had documented 
LVH. Compared with atenolol-treated patients, pa- 
tients who received losartan had significantly greater 
reductions in left ventricular mass index (LVMI) (-21.7 
[21.8] vs -17.7 [19.6] g/m2; P = 0.021) and LVH as 
determined by Sokolow-Lyon voltage on electro- 
cardiogram (-2.5 vs-0.7 mm; P < 0.001) or Cornell 
voltage-duration product (-200 vs -69 mm • ms; P < 
0.001), despite similar reductions in BP. 69,70 
Other AliAs have shown similar actions to losartan 
with regard to reduction of myocardial fibrosis. 71-78 
Valsartan has been reported to inhibit myocardial fi- 
brosis (interstitial collagen content) in post-MI rats 
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• .-..,~.,-.,.'-', ~ ,  v i:4~..<.;i i t - .~  .<,~ 
- . .  + ' ::..~.;.'<!! .-' I "  | ~, , '  -.,",. , / ,~ ' .  ,,. '. " 
• . ,,... , .... ~;.r, . . ; ,~ . . . .  ! * ~ , , " " ' ' i  ",'~" ~ . , . i .  . . 
,~.. • . .. :i , , . : -~  ~ i ~ . ~.' . ' ,  ~. ' ,  ,44;:  : :.-,. 
. .... - - ' .  .'<"- .""' J, ~ : l  • ,  '+. ' , '¢#i  r~.  " t : .~ l ! i . r : ' .  • , 
• ;! ..'? i 
,.., , ; . .~ '  L '4"d  "~.': .~  ....,,-' . • , • , . 2 .  I , ~ . "  ~, '  .~  z~.-':,2 ." 
,~" r.~.t:<..~%"...',i;v~,~ :,;.,~;~ '1.~.;.'"", <r  I~, 'Y2,[  . -":".~') 
" ,,.'.',A2~.-'. i~"]':~ ". #'II • H f t t  ., " -~,ilf.l~" "A,':.:;-'"~.:. 
". ' : " :" . ' ;q" , ;;.,."<7#, +" ~/, ," " "  ~ " " " r<e ~.#~; - :  ,,/ 
• ,,4, , ,- ' . . .  , , -~-  ': i , ' I  : ; " "  " ,,> 7,' ~ . j " -  
• " - ' l l  .,.. : :...~-'~., . ' . i (~  V .  ~ .~ ...,. 4 - • ,  ,;," • : :~ . , . : . . . . . . . ; . . , " . . . , : :<~. . . , , , , . '~ .~ a~#-~.~.: ...i" .:. 
- ' ; -  ¢ %:. .L  ~_ " . /~ .  ,.ll @:.;,t" ~ - e l l  .~.7m'"/,;. .  ,' . ; ' ,~..  " 
\ . . -  ,. - ,¢ .~ ,g  - .  . I t .  ._l. I " ~ ,, , ,  , - . .~ , 
• ~. .k  ..~,,,::A-,+, ./.4~.7.~ !~ - :- ' '  " : ' ' ' '~  : " " . . '  '.%,:~i:.~" ,',,.Z~4~ ~..t . -4 .  ~ , v  .~  , 
, " "L I~ I *  " " 71 ~ r ~ " ~  " l  i" ~ + • "' ," . '  , 
- ~,~ , - .  , - , ,~ .n . .~:~ ,7 -#,11 '  l l l ! l~  i~  i i " - , -  
" ". '> ..;~r,:.~ "..t.;~.-~,~>,, ~, ,y" , . . . .  ' .-~!.,%- ~_ l  ~ . . . , :  • 
• "~ ~'-'.,'~',.~-.:. r"  &'.~*.'~ i~'fl-.]~'~ ...7~' ' . : ' l t~  Z , I  '~." v ,.~ " - . ?~?c_ :'.? ,'c L#;,t.i ~%,r~Li l ' . '  t tT~'  [~ ,-." .,.~. 
~4~: ; " ; / ; I~ I " : . .  , : . .~:<l~xr  ~ ~ ..": 
"; "2 ' ' . - '  ? .~.~ ,, ~",! . 
. k  ,..-". 
:....~':./", ~ , "~ - "~-~ ,~.~-.D-,.. 1 
: . : v  -. ,.< , 
,~:.,.,,,,~..~.-,,,..:..< .-. ./.. 
.. il<:'<" ~ . , "~. - ,  .~  .,,... ~ / .  .,,, 
'~ : , ;  ~",.~71." : ;~ ", ' . . : . -~ 
~. .~." . .  ~ '  7%"  -~ ' . , .  " . , . .  ~ , , ,~  
Figure 2. H is to log ic  sect ion  o f  myocard ia l  spec imen b iopsy  f rom a hyper tens ive  pat ient  w i th  severe myocard ia l  f i -  
bros is .  The  image used p ic ros i r ius  red sta in and  20× magn i f i ca t ion .  (A )  Before  chron ic  t reatment  w i th  
losar tan .  (B)  A f te r  losar tan .  
836 Vo lume 28  Number  6 
J. Dfez 
(P < 0.05 vs placebo)71; however, the role of BP changes 
is unclear. Similarly, candesartan has been reported to 
reduce collagen synthesis n cell culture 79 and to reduce 
myocardial fibrosis in animal models. 73-78 Although 
evidence for the action of candesartan or valsartan i
humans is limited, a randomized, double-blind study 
comparing valsartan with atenolol found that treat- 
ment with valsartan was associated with significant 
regression of LVH in largely untreated patients with hy- 
pertension. 8°Patients who received valsartan exhibit- 
ed a decrease in mean (SD) LVMI (from 127 [23] g/m 2 
at baseline to 106 [25] g/m 2 at 8 months; P < 0.001). 
Similarly, atenolol-treated patients experienced a signifi- 
cant decrease in mean (SD) LVMI (from 127 [25] g/m 2 
at baseline to 117 [27] g/m 2 at 8 months; P < 0.009). 
Alternative Mechan isms 
The arrhythmogenicity of All may be mediated 
through alternative mechanisms. In fact, in guinea-pig 
isolated atria, AII increased norepinephrine r lease in- 
duced by electrical field stimulation (55% maximal 
augmentation at 10 -6 mol/L AII), and the effects of 
10 -6 mol/L and 10 -7 mol/L AII were completely inhib- 
ited by 10 -6 mol/L losartan. 81 Thus, given the evidence 
that norepinephrine may have proarrhythmogenic ef-
fects, 82 it is possible that losartan may have antiar- 
rhythmic properties via inhibition of norepinephrine 
release in cardiac sympathetic nerves. 
Preliminary experimental in vitro data obtained using 
guinea-pig ventricle and isolated guinea-pig ventricu- 
lar myocytes uggest that losartan i hibits cardiac de- 
layed rectifier K + currents, thus providing a molecular 
basis for the modification of the atrial and ventricular 
action potentials. 83 This property may have relevance 
when considering the antiarrhythmic properties of 
losartan, given the evidence that losartan reduces QT 
dispersion, which is an electrocardiographic measure 
of ventricular repolarization and is also a risk marker 
for ventricular tachyarrhythmias. 84 This study analyzed 
QT intervals (calculated by a single, blinded investiga- 
tor using standard 12-lead electrocardiography) in a 
total of 90 heart-failure patients at baseline and after 
active treatment with losartan (n = 47) or captopril 
(n = 43). QT dispersion (QTd, defined as the difference 
between maximum and minimum QT intervals [ie, be- 
ginning of the QRS complex to end of the T wave]) 
increased in patients receiving captopril (from mean 
[SD] 64 [25] ms at baseline to 74 [25] ms at end of 
study; P = 0.008) but not in patients receiving losartan 
(from mean [SD] 60 [21] ms at baseline to 60 [22] ms 
at end of study; P = NS). The difference between groups 
was significant (P = 0.01). 
LOSARTAN AND BLOOD VULNERABILITY 
I n f lammat ion 
Rupture of the sclerotic plaque and the associated 
formation of thrombus are the most important mecha- 
nisms leading to complications associated withathero- 
sclerosis. 85 All promotes inflammation via induction 
of nuclear translocation of nuclear factor 1( B (NF-~d3), 
thereby upregulating expression of inflammatory cy- 
tokines in monocytes, endothelial cells, and VSMCs. 86,87 
In aortic segments from hypercholesterolemic rabbits, 
losartan was associated with significantly reduced ac- 
tivation of NF-~:B compared with a control group on 
a high-cholesterol diet (P < 0.05 [n = 4 in each group]); 
it was postulated that this might have been the result 
of inhibiting degradation of its inhibitor, I~:-B0~. 88 In 
addition to upregulating NF-~:B, All induces mono- 
cyte chemotaxis by upregulating monocyte chemoat- 
tractant protein 1 (MCP-1) and C-C chemokine 
receptor 2 (MCP-1 receptor). 89-91 Losartan has been 
reported to completely inhibit the binding of mono- 
cytes to human aortic endothelial cells induced by 
All in culture (P < 0.05). 92 In addition, losartan in- 
hibits basal MCP-1 expression, 93,94 as well as LDL-C- 
stimulated MCP-1 expression. 93 Losartan therapy 
reduced circulating levels of MCP-1 in hypercho- 
lesterolemic monkeys after 6 weeks (from -105 to 
70 ng/mL; P < 0.05). 32 Eighteen healthy volunteers 
who received losartan (50 mg/d for 6 weeks) in a ran- 
domized, double-blind, crossover study experienced a 
significant reduction in MCP-1 concentration (from 
560 to 423 ng/mL at week 6; P < 0.01). 95 Similar ac- 
tions of candesartan and irbesartan have been report- 
ed in hypertensive patients or healthy volunteers, 17,96 
and would suggest hat some of the actions of losar- 
tan on macrophage chemotaxis may be mediated by 
the AT 1 receptor and common to the AliAs. 
Arachidonic acid metabolism plays an important role 
in acute ischemic syndromes affecting the coronary or 
cerebrovascular territory, as reflected by biochemical 
measurements of eicosanoid biosynthesis and the re- 
sults of inhibitor trials in these settings. 97 In particular, 
the clinical efficacy of low-dose aspirin in reducing the 
short-term complications f acute MI and acute is- 
chemic stroke, as well as in preventing vascular ecur- 
rences, has focused attention on the cyclooxygenase 
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(COX) pathway of arachidonic acid metabolism and 
its bioactive products. 98 Experimental nd clinical tools 
developed uring the past 10 years have allowed one 
to hypothesize a role for COX-2-derived prostanoids 
and matrix metalloproteinases in atherosclerotic dis- 
ease progression and its thrombotic omplications. 99
All has been found to upregulate COX-2 mRNA in 
vitro in rat VSMCs, 1°° thereby increasing prostaglandin 
synthesis, an effect that was completely blocked by 
losartan. 1°° Similarly, All upregulates the expression 
of both COX-2 mRNA (6.5-fold increase at 3 hours; 
P < 0.001) and protein and stimulates the production 
of COX-2-dependent prostaglandins in cultured human 
aortic VSMCs in vitro. 1°1 Pretreatment of VSMCs 
with losartan (1 pM for 30 minutes) in vitro attenuat- 
ed the effects of All on the expression of the COX-2 
protein (without altering the expression of COX-l) 
and also inhibited the MI-stimulated release of prosta- 
glandin E 2 (PGE2).I°I A study in patients with symp- 
tomatic carotid artery stenosis treated with irbesartan 
or chlorthalidone for 4 months before endarterectomy 
has also reported that irbesartan was associated with 
a decrease in inflammation and inhibition of COX-2/ 
PGE2-dependent synthase xpression i  atherosclerot- 
ic plaque. 1°2 The authors uggested that this effect may 
contribute to plaque stabilization. 
Thrombosis 
Tissue factor (TF) initiates coagulation through bind- 
ing to factor VII. 1°3 In situ hybridization and immuno- 
histochemistry techniques (using a specific riboprobe 
for TF mRNA and a polyclonal antibody directed 
against human TF protein) have identified TF-producing 
cells in normal human vessels and atherosclerotic 
plaques. 1°4 Wilcox et al 1°4 reported the absence of TF 
mRNA and protein in endothelial cells lining normal 
internal mammary artery and saphenous vein sam- 
pies, although TF was synthesized in scattered cells 
present in the tunica media as well as in fibroblast-like 
adventitial cells surrounding vessels. In contrast, 
vessels with atherosclerotic plaques contained many 
cells synthesizing TF mRNA and protein, including 
macrophages present as foam cells and monocytes ad- 
jacent o the cholesterol clefts. 1°4 AII has been report- 
ed to increase TF expression in cultured endothelial 
cells and VSMCs. 1°5J°6 Losartan has been reported to 
reduce expression of TF in leukocytes from healthy 
volunteers 1°7 and in cultured VSMCs exposed to AII. l°s 
In addition, several AIIAs (ie, irbesartan, candesartan, 
valsartan) have been shown to reduce TF expression 
in hypertensive patients, transgenic rats, or human 
cultured monocytes. 1°9-111 
All also promotes coagulation by inhibiting the fi- 
brinolytic system by inducing plasminogen activator 
inhibitor-1 (PAI-1) in the vasculature. 112 Conflicting 
data suggest that losartan may mediate antifibrinolytic 
activity via reduction of PAI-1 expression and activi- 
ty, 113-117 and other reports suggest that losartan may 
inhibit fibrinolysis by alternate actions through pre- 
vention of platelet aggregation (Figure 3). 118,119 The 
different observations about PAI-1 activity and ex- 
pression may reflect he manner in which the analyses 
were conducted, such as timing of sample collection 
and duration of treatment, u3 Reduction of PAI-1 levels 
by candesartan, valsartan, and irbesartan would, how- 
ever, suggest that All-mediated inhibition of fibrinoly- 
sis may be affected by the AT 1 receptor. 17,109,120,121 
It is widely acknowledged that transformation of 
arachidonic acid into prostaglandins such as prosta- 
glandin F2c ~ (PGF2~) and thromboxane a 2 (TXA2) is as- 
sociated with increased platelet aggregation. Altered 
40- 
30- 
" - -  O~ 
v 
c- c- 
O 20- -~.~ 
E~ 
0 ~ 10- 
~-~ O- - -  U a_ 
-10- 
I I 
Losartan Placebo 
Figure 3. Increase in the extent of platelet aggre- 
gation at median effective concentration 
producing a response of 50% of the maxi- 
mal response, mediated by a selective 
thrombin receptor agonist in 9 hyperten- 
sive patients administered Iosartan 50 mg/d 
or placebo for 4 weeks. Adapted with 
permission. 119 
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platelet function plays a critical role in the develop- 
ment of thrombi. TXA2, the main product of platelet 
arachidonic acid metabolism, is a potent inducer of 
platelet aggregability. 122 Platelet shape change is an 
early phase of platelet activation that precedes platelet 
aggregation. AII has been found to induce platelet 
shape change in human platelets from healthy volun- 
teers, as suggested by a significant increase in median 
platelet volume (P < 0.004). 123 In -57% of subjects 
(n = 8) who experienced a marked increase in median 
platelet volume (>0.4 fL), losartan significantly inhib- 
ited platelet shape change induced by AII (from 5.85 fL 
with AII alone to 5.55 fL after AII plus losartan after 
10 minutes; P < 0.008). 123 Similar changes were also 
induced by the TXA 2 analogue U46619.123 Further- 
more, several studies have reported the inhibition of 
U46619-induced platelet aggregability by losartan in 
human, canine, or rat platelets in vitro. 124-131 The in- 
hibitory effect of losartan on platelet aggregability ap- 
pears to be greater with the parent compound than 
with its metabolite EXP3174.124,126,127 Losartan- 
dependent inhibition of PGF2~ formation has also 
been reported in hypertensive patients after o al ad- 
ministration of losartan 100 mg (Figure 4). 132 Irbesartan 
also inhibited the TXA 2 receptor in platelets, but can- 
desartan and valsartan appeared to have little or no 
effect on platelet aggregability. 12s-13° 
EM ERGING ASPECTS 
Serum Uric Acid 
Hyperuricemia s common in patients with CV and 
kidney disease. 133 In the general population, hyperten- 
sive patients, and those with preexisting CV disease, 
serum uric acid (SUA) may represent an important 
predictor of CV events. 134 However, the link between 
SUA and risk of CV events is controversial (for 
detailed review, see Alderman and Aiyer135). Studies 
have reported that SUA is associated with the activation 
of circulating platelets, 136 upregulation of MCP-1,137 
impaired endothelial nitric oxide release, 13s VSMC 
proliferation, 139-141 and induction of COX-2, TXA, 
and other cytokines. 139-142 In a multivariate analysis 
of patients who had experienced ischemic stroke, high 
SUA was associated with poor outcome (ie, death 
or life in care) and with subsequent vascular events 
(ie, MI, ischemic stroke, or vascular death), based on 
data from 3731 patients (SUA measurements were 
available in 2498). 143 
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Figure 4. Losartan-dependent inhibition of prostaglandin F2~ (PGF2~) formation in serum samples of 5 patients 
after oral administration of Iosartan 100 mg or placebo. PGF2~ was measured by enzyme-linked im- 
munosorbent assay. *P < 0.01 versus placebo. Reproduced with permission. 132 
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Losartan was reported to decrease SUA in healthy 
Japanese male subjects in a dose-dependent manner, 
with single doses ranging from 25 to 200 mg. 144 In 
that study, SUA measured at 4 hours after administer- 
ing single oral doses of losartan 25, 50, 100, or 200 mg 
(n = 6), or placebo (n = 3), was decreased from base- 
line by a mean of 0.32 mg/dL (with losartan 25 rag), 
0.77 mg/dL (with losartan 50 rag), 1.25 mg/dL (with losar- 
tan 100 rag), and 1.33 mg/dL (with losartan 200 rag). 
Losartan has been found to produce auricosuric ef- 
fect. 145 Data from Sweet et a1146 suggest that the par- 
ent molecule, not its active metabolite EXP3174, is 
the active agent blocking uric acid absorption. Fur- 
thermore, the effect of losartan on SUA does not ap- 
pear to be shared with other members of the AIIA 
class. 147-149 Recently, the LIFE study reported a possi- 
ble association of baseline SUA with MI, stroke, or 
CV death (HR, 1.024 per 10 l~mol/L [95% CI, 1.017- 
1.032]; P < 0.001). 15° Although SUA levels increased 
in both the losartan and atenolol groups, patients who 
were treated with losartan had a significant attenua- 
tion of the increase in SUA from baseline. 15° The in- 
crease from baseline in mean (SD) SUA was greater in 
atenolol-treated subjects than in losartan-treated sub- 
jects (44.4 [72.5] vs 17.0 [69.8] l~mol/L; P < 0.001). 
The association of SUA with CV events was signifi- 
cant in women (HR, 1.025 [95% CI, 1.013-1.037]; 
P < 0.0001) and remained so after adjustment for 
the Framingham risk score (HR, 1.013 [95% CI, 
1.00-1.025]; P < 0.046). 15° However, the relationship 
between baseline SUA and CV events was not signifi- 
cant in men (HR, 1.009 [95% CI, 0.998-1.019]). 
SUA as a time-varying covariate was also associated 
with events in the entire population (P < 0.001); this 
association was strong in women (P < 0.001), but was 
not present in men (P = NS). 15° The underlying rea- 
sons for this apparent gender difference are unclear, 
however. 
The Losartan Metabolite EXP3179 
Given the differences in the effects of losartan on 
platelet aggregability, compared with other AliAs, 
losartan's metabolite has been identified and its effects 
on COX-2 and its role in platelet aggregability inves- 
tigated. 132 Losartan is metabolized by the liver pri- 
marily by the cytochrome P450 (CYP) 2C (CYP2C) 
enzymes, with some additional involvement of the 
CYP3A enzymes (Figure 5). 151 Losartan is biotrans- 
formed to the active carboxylic acid derivative 
EXP3174, which has been shown to be 40 times more 
potent at blocking the AT 1 receptor than losartan. 152 
EXP3179, an intermediate aldehyde compound in the 
metabolism of losartan, has also been identified 151 
and reported to have extremely low (if any) affinity 
for the AT 1 receptor. 132 Plasma levels of EXP3179 
after administration of l sartan have been reported to 
increase at 2 hours and peak at 3 to 5 hours before 
disappearing at-6 hours postadministration. 132 
Glucuronidation P450 Oxidation 
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CI CI CI CI N /~ N/~ N/ /~ N/~ 
N ~q~.~ NK(Glu) N - - .~  NK N ~/ )  NH N ~q.~ NH 
N N N N 
Losartan EXP31 79 EXP31 74 
Figure 5. Schema for the cytochrome P450 oxidative biotransformation of Iosartan to its active carboxylic acid 
metabolite, EXP3174, and its aldehyde intermediate, EXP3179. 
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Recently, Kramer et a1132 reported that EXP3179 
had anti-inflammatory activities that were indepen- 
dent of the AT 1 receptor and were mediated by regu- 
lation of COX-2 mRNA expression. EXP3179 was 
thought to elicit COX-2 inhibitory properties by block- 
ing COX-2 mRNA upregulation and PGF2~ synthesis 
induced by All and bacterial lipopolysaccharide 
(LPS), an AT 1 receptor-independent proinflammatory 
stimulus, in human endothelial cells. 132 EXP3179 also 
prevented upregulation of ICAM-1 induced by LPS in 
these cells. 132 Finally, EXP3179 abolished platelet ag- 
gregation induced by arachidonic acid and U46619.132 
Importantly, treatment of hypertensive patients with a 
single dose of losartan 100 mg resulted in a decrease 
in platelet aggregability at -6 to 8 hours after admin- 
istration, which coincided with peak plasma concen- 
trations of EXP3179.132 The anti-inflammatory and 
antiaggregatory effects of losartan appear to be par- 
tially independent of its blockade of the AT 1 receptor 
and may be related to alternative mechanisms elicited 
by its metabolite, EXP3179. 
Research using the endothelium of intact rat aorta 
and endothelial cells in vitro has found that EXP3179 
stimulates endothelial nitric oxide synthase (eNOS) 
phosphorylation a d suppresses tumor necrosis factor- 
R-induced endothelial cell apoptosis by activating the 
vascular endothelial growth factor receptor-2 signaling 
pathway. 153 The magnitude for EXP3179-stimulated 
phosphorylation f eNOS was much greater than that 
of EXP3174, and the median effective concentration 
producing a response of 50% of the maximal response 
(ECS0) was significantly lower (mean [SD] -logECS0, 
8.2 [0.1] vs 5.4 [0.2] mol/L, respectively), suggesting 
an AT 1 receptor-independent beneficial effect of the 
losartan metabolite EXP3179 on the endothelium. 
Finally, a study identified EXP3179 as a partial per- 
oxisome proliferator-activated receptor Y (PPAR-y) 
agonist. 154 In fact, EXP3179 was found to promote 
3T3-L1 adipocyte differentiation, induce PPAR- 7 tar- 
get gene expression, and directly activate the PPAR- 7- 
ligand-binding domain (LBD). EXP3174 did not induce 
PPAR-7-LBD activation and failed to regulate adipocyte 
differentiation of PPAR- 7 target gene expression. 
EFFECTS OF ATENOLOL:  
INTERPRETATION OF LIFE STUDY DATA 
Although the results of the LIFE study may have been 
due to a possible benefit of losartan other than BP 
control, an alternative interpretation of the LIFE data 
has also been put forth: the results could be partly due 
to lack of benefit of atenolol. In this regard, a meta- 
analysis of randomized trials has suggested that 
13-blockers (and specifically atenolol) may not provide 
equivalent reduction in CV events compared with 
other antihypertensive agents. 155 The recent meta- 
analysis by Carlberg et a1155 disputed the choice of 
atenolol as an appropriate comparator in clinical tri- 
als involving patients with hypertension. That analy- 
sis focused on 4 randomized trials that compared 
atenolol with no treatment and 5 trials that compared 
atenolol with other antihypertensive drugs in hyper- 
tensive patients. In the studies comparing atenolol and 
placebo, no differences in outcome were apparent 
with respect o all-cause mortality (relative risk [RR], 
1.01), cardiovascular mortality (RR, 0.99), or MI 
(RR, 0.99); stroke risk appeared to be slightly lower 
in the atenolol group (RR, 0.gs), but this was not sta- 
tistically significant. In 5 studies comparing atenolol 
with other antihypertensives (HCTZ/bendroflumethi- 
azide, captopril, losartan, or lacidipine; 17,671 patients 
followed over a mean of 4.6 years), a significantly 
higher risk of mortality (RR, 1.13 [95% CI 1.02- 
1.25]) was found to occur with atenolol compared 
with the other active treatments. 
These results have been challenged by a separate 
meta-analysis conducted by Edelman et al. 156 In their 
meta-analysis of 6 randomized outcomes trials, a 
13-blocker (including atenolol-based studies, other 
13-blocker studies [ie, propranolol alone, atenolol/ 
metoprolol/pindolol combined], and iuretic-based 
studies in which atenolol was used as add-on therapy) 
was associated with a 26% risk reduction in all CV 
events (P < 0.001), a 19% risk reduction in CV death 
(P = 0.001), a 34% risk reduction in stroke (P < 0.001), 
and a 20% risk reduction in coronary heart disease 
(P < 0.001), compared with placebo or no treatment. 
The investigators suggested that a possible reason for 
the differences in findings between the 2 analyses may 
involve the types of study selected in each case. In this 
regard, it is important to note that in the meta-analysis 
by Carlberg et al, 155 2 of the 4 studies evaluated the 
use of atenolol for secondary (not primary) prevention 
of stroke and secondary cerebroprotection. 
Another possible xplanation for the difference be- 
tween stroke risk with losartan and atenolol bserved 
in LIFE may involve differences in central pulse pres- 
sures between groups. 157 According to results from the 
Anglo-Scandinavian Cardiac Outcomes Trial Conduit 
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Artery Function Evaluation (ASCOT CAFE) study in 
hypertensive patients, 158 central aortic pressures may 
be a better predictor of events such as stroke and MI 
than conventional brachial BE ASCOT CAFE was a 
substudy of ASCOT and measured central and brachial 
BPs in 2073 hypertensive patients receiving either 
an amlodipine/perindopril regimen or an atenolol/ 
bendroflumethiazide regimen. The CAFE study found 
that central aortic pulse pressure was 3 mm Hg lower 
in the amlodipine-based regimen than in the atenolol- 
based regimen (P < 0.001), whereas brachial pulse 
pressure was slightly higher (0.9 mm Hg) but not sig- 
nificantly different. Although these findings suggest 
that BP-lowering agents may have different effects on 
central aortic pressures, which may, in turn, translate 
to different clinical outcomes, it must be borne in 
mind that the brachial BPs were well controlled but 
not identical between study groups. The mean brachial 
diastolic BP was found to be 1.6 mm Hg lower in pa- 
tients randomized to amlodipine (P < 0.001). Mthough 
differences in central aortic pressures may have con- 
tributed to the stroke benefit observed in the LIFE 
study, 159 central BP measurements were not part of 
the study methods. Thus, the concern cannot be con- 
firmed or refuted. 
CONCLUSIONS 
A losartan-based regimen was associated with a signifi- 
cantly lower rate of stroke than was atenolol in hyper- 
tensive patients with LVH in the LIFE study, despite 
similar BP reductions. This review of the literature 
suggests that losartan (and perhaps other AIIAs) may 
possess a number of properties, independent of its anti- 
hypertensive effects, that may be associated with de- 
creased vulnerability of the plaque, myocardium, and 
blood. Although some of these effects may be shared 
by other AliAs or other antihypertensive classes (eg, 
angiotensin-converting enzyme inhibitors), some of 
losartan's effects appear to be molecule specific. 
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